( December 4, 2025, 1:06 PM EST) -- WASHINGTON, D.C. — A biopharmaceutical company’s patent on a cancer therapy called antibody-drug conjugates (ADCs) is invalid for lack of written description and lack of enablement, a Federal Circuit U.S. Court of Appeals panel held in two opinions that reversed a Texas federal judge’s refusal to grant judgment as a matter of law (JMOL) to defendant biopharmaceutical entities and dismissed as moot a related appeal of a U.S. Patent Trial and Appeal Board (PTAB) ruling....